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GliomaSignal transducer and activator of transcription 3 (Stat3) is a transcription factor that is involved in cell survival
and proliferation and has been found to bepersistently activated inmost human cancersmainly through its phos-
phorylation at Tyr-705. However, the role and regulation of Stat3 Ser-727 phosphorylation in cancer cells
have not been clearly evaluated. In our ﬁndings, correlation studies on the expression of CK2 and Stat3
Ser-727 phosphorylation levels in human glioma patient samples as well as rat orthotopic tumor model show
a degree of negative correlation. Moreover, brain tumor cell lines were treated with various pharmacological
inhibitors to inactivate the CK2 pathway. Here, increased Stat3 Ser-727 phosphorylation upon CK2 inhibition
was observed. Overexpression of CK2 (α, α′ or β subunits) by transient transfection resulted in decreased
Stat3 Ser-727 phosphorylation. Stat3 Tyr-705 residuewas conversely phosphorylated in similar situations. Inter-
estingly,we foundPP2A, a protein phosphatase, to be amediator in the negative regulation of Stat3 Ser-727phos-
phorylation by CK2. In vitro assays prove that Ser-727 phosphorylation of Stat3 affects the transcriptional activity
of its downstream targets like SOCS3, bcl-xl and Cyclin D1. Stable cell lines constitutively expressing Stat3 S727A
mutant showed increased survival, proliferation and invasionwhich are characteristics of a cancer cell. Rat tumor
models generated with the Stat3 S727Amutant cell line formed more aggressive tumors when compared to the
Stat3WT expressing stable cell line. Thus, in glioma, reduced Stat3 Ser-727 phosphorylation enhances tumorige-
nicity which may be regulated in part by CK2–PP2A pathway.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Glioblastoma multiforme (GBM) is the most aggressive and malig-
nant form of brain tumor in human with very short patient survival [1].
Amongst the many causal reasons of GBM, alterations and perturbationsf transcription 3; CK2, casein ki-
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. This is an open access article underin the molecular signaling pathways play a major role. Several signaling
pathways have been implicated in the progression of GBM including
phosphoinositide-3-kinase (PI3K), Ras-MAPK and tyrosine kinase signal-
ing pathways viz. EGFR and VEGFR [2].
Apart from these conventional pathways, kinases like CK2 are
now emerging as crucial molecules for GBM progression [3]. CK2 is a
ubiquitous and highly conserved serine/threonine kinase with two
alpha (catalytic) and two beta (regulatory) subunits [4]. This protein
has been involved in the regulation of cellular growth and proliferation,
transformation, apoptosis and senescence [5,6]. Increased expression
and activity of CK2 in several cancers mark it as an important target
for speciﬁc therapies [6]. Elevated levels of this protein have also been
reported in human GBM tumor specimens where inhibition of CK2
could sensitize these cells to tumor necrosis factor-α induced apoptosis
[7]. A CK2 inhibitor has been reported to induce antitumor activity
in mouse xenograft model of human glioblastoma [8] while apigenin,
another CK2 inhibitor, was found to modulate DNA damage response
of GBM cells though it could not radiosensitize them [9]. CK2 can also
induce glioma cell invasion by mediating α-catenin phosphorylationthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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transcriptional activity [10].
In addition to several substrates already existing for CK2, novel
interacting partners are now emerging. It has been recently reported
that CK2 activates the Jak–Stat signaling pathway by associating with
Jak1 and Jak2 but not Stat3 in myelo-proliferative disorders [11]. Stats
are latent transcription factors that mediate cytokine- and growth fac-
tor-directed transcription. Stat3 is persistently activated in many
human cancers, including glioma, leukemia,myelomas, breast, prostate,
pancreatic, lung and ovarian cancers. In tumors, active Stat3 is required
for either transformation, enhancing proliferation or blocking apoptosis
[12]. The role of Stat3 in GBMpathogenesis is well documented [13–15].
Though Stat3 transcriptional activity is reﬂected by phosphorylation at
both its tyrosine and serine residues, pStat3Tyr705 has been implicated
in most cases of disease progression [16,17]. Elevated levels of serine
phosphorylated Stat3 in GBM have been reported in a single study
[18] but the mechanism of activation is poorly understood.
In this study, we focus on the regulation of Stat3 Ser-727 phosphor-
ylation by CK2 in glioma. This regulation was found to be negative and
led to increased Stat3 transcriptional activity. Here, PP2A was found to
maintain the decreased phosphorylation levels of Stat3 Ser-727 which
is controlled by CK2. Reduced Ser-727 phosphorylation of Stat3 with
concomitant increase in Tyr-705 phosphorylation leads to enhanced
rate of proliferation and invasive property of glioma cells thereby estab-
lishing Ser-727 residue of Stat3 to be antagonistic to tumor formation.
CK2, thus, crosstalks with the Stat3 signaling pathway through PP2A
leading to the progression of more aggressive forms of glioma.
2. Materials and methods
2.1. Cell culture, transfection and drug treatments
The human cell lines HEK293 (embryonic kidney), U87MG, DBTRG-
05MG (glioma) and rat cell line C6 (glioma) used in the study were
obtained from ATCC (Manassas, VA, USA) and NCCS (Pune, India)
respectively. Cells were cultured in DMEM supplemented with 10%
heat-inactivated FBS, 2000 units/l penicillin and 2 mg/l streptomycin
(Invitrogen, Life Technologies, Grand Island, NY, USA). All cells were
maintained at 37 °C in a humid incubator with 5% CO2. Transfections
of different DNA constructs were performed using either Attractene
(Qiagen, Gaithersburg, MD, USA) according to manufacturer's instruc-
tions or calcium phosphate protocol as described previously [19]. The
following drugs/inhibitors, dissolved in DMSO, were used in this
study: TBCA (10 μM), LY294002 (20 μM), U0126 (15 μM), and calyculin
A (100 nM) (Calbiochem, Darmstadt, Germany), D-sorbitol (0.5 M) and
okadaic acid (1 μM) (Sigma Aldrich, Seelze, Germany). Incubation times
are indicated in the ﬁgure legends. Stable C6 cells were selected using
either neomycin (2 mg/ml) or hygromycin (500 μg/ml) depending on
the plasmid used.
2.2. Expression plasmids
pGZ21dx-GFP-CK2α, pCDNA3.1 H(+)-Stat3 WT and pCDNA3.1-
Stat3-(S727A) were previously described [19,20]. pGZ21dx-GFP-PP2A-
Cα plasmid was cloned from HEK293 cells using the primers PP2Acα-
F: 5′-AATGAATTCATGGACGAGAAGGTGTTC-3′ and PP2Acα-R: 5′-AATG
TCGACCAGGAAGTAGTCTGGGGT-3′. pRS2-(CK2alpha′,CK2beta) and
pRS3-(CK2alpha, CK2beta) constructs were obtained from Addgene
(Cambridge, MA, USA). All constructs were veriﬁed by sequencing.
2.3. Cell lysis, immunoprecipitation and immunoblot analysis
Whole-cell lysates (WCLs) were prepared by lysing the cells in ice-
cold buffer as described earlier [21]. SDS-PAGE andWestern blot analyses
were performed using standard procedures. For coimmunoprecipitation
experiments, 1 mg of total protein from lysates was subjected toimmunoprecipitation as described previously [22]. Antibodies for
pStat3Y705, pStat3S727, Stat3, CK2α, SOCS3 and Bcl-xl were purchased
from Cell Signaling Technology (Danvers, MA, USA). Antibodies for
MMP9, MMP2, VEGF, Actin and Lamin B were from Santa Cruz Biotech-
nology (Dallas, Texas, USA). Blots were evaluated by using Enhanced
Chemi-luminescence (ECL) reagent according to themanufacturer's pro-
tocol (GE Healthcare, Pittsburgh, USA).
2.4. Quantitative real time PCR (qRT-PCR)
Total RNA was extracted using TRIzol reagent (Invitrogen, NY, USA)
according to the manufacturer's instructions. For each sample, 2 μg
of RNA was converted to cDNA using RevertAid First Strand cDNA
Synthesis Kit (Thermo Scientiﬁc, Glen Burnie, Maryland, USA) and was
subsequently used for qRT-PCR analysis using Power SYBR Green
Master Mix on 7500 Fast real time PCR system (Applied Biosystems,
Foster City, CA, USA). 18S rRNA (for human glioma cells) and RPL19
(for C6 glioma cells) served as internal controls (normalization) and
calibrator controls were chosen appropriately.
Listed below are the primers (human and rat) for the qRT-PCR
analysis:
bcl-xl: F-5′-ACCCCAGGGACAGCATATCA-3′,
R-5′-TGCGATCCGACTCACCAATA-3′
SOCS3: F-5′-GGCCACTCTTCAGCATCTC-3′,
R-5′-ATCGTACTGGTCCAGGAACTC-3′
Cyclin D1: F-5′-CCGTCCATGCGGAAGATC-3′,
R-5′-GAAGACCTCCTCCTCGCACT-3′
MCL1: F-5′-AAAGAGGCTGGGATGGGTTT-3′,
R-5′-CAAAAGCCAGCAGCACATTC-3′
18S: F-5′-GCTTAATTTGACTCAACACGG-3′,
R-5′-AGCTATCAATCTGTCAATCCTGTC-3′
BCL2: F-5′-CCGGGAGAACAGGGTATGATAA-3′,
R-5′-CCCACTCGTAGCCCCTCTG-3′
Myc: F-5′-TGTATGTGGAACGGCTTCTC-3′,
R-5′-CCTGGTAGGGGTCCAGCTTC-3′
RPL19: F-5′-ATCGCCAATGCCAACTCT-3′,
R-5′-GAGAATCCGCTTGTTTTTGAA-3′.
2.5. Luciferase reporter assay
c-jun promoter region (−1780 to +731) containing Stat3 binding
site (GAS sequence — TTCCCGGAA) was ampliﬁed from genomic DNA
using sense oligonucleotide: 5′-GAGAATTCCAAGTTCAGAAGCAG-3′
and antisense oligonucleotide: 5′-GAGCTACCCGGCTTTGAAAAGT-3′
containing XhoI and HindIII restriction sites respectively. The resulting
fragment was inserted into pGL3-basic plasmid to generate pGL3–c-
jun construct. HEK293 or C6 cells were transiently transfected with
the pGL3–c-jun construct along with Renilla luciferase vector (pRL-TK)
and respective gene constructs as per experimental interest. 36 h
post-transfection, cells were treated with respective inhibitors or acti-
vators for the time periods indicated in the ﬁgure legend. Cells were
harvested using Dual Luciferase Reporter Assay System (Promega,
Madison, USA) following the manufacturer's protocol and measured in
VICTOR X Multilabel Plate Reader (PerkinElmer, Waltham, MA, USA).
Quantiﬁcation was based on three independent experiments.
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Formalin Fixed Parafﬁn Embedded (FFPE) post-surgical human glio-
ma tissue samples (n = 23) were collected from patients diagnosed
with glioma following all medical and ethical regulations and with for-
mal approval from the ethical committee of both CSIR-IICB and Park
Clinic (source). For immunohistochemical staining, previously de-
scribed protocol was followed [20]. Primary antibodies for pStat3S727
and CK2α were from Abcam (MA, USA), while pStat3Y705 antibody
(XP-monoclonal)was obtained fromCell Signaling Technology (Danvers,
MA, USA). Imageswere captured using DP71 camera (Olympus, Japan) in
BX-61 microscope (Olympus, Japan) and analyzed using Image Pro
Plus imaging software (Media Cybernetics, Bethesda, USA). A semi-Score p-va
Kruskal -Wallis H=8.96 0.00
Wilcoxon-Mann-Whitney U=130 0.00
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Fig. 1. Phosphorylation of Stat3 at Ser-727 occurs less frequently than CK2 expression in glioma.
and adjoining normal brain regions of 6 human glioma patient samples stainedwith antibodies
A section from each image has been magniﬁed in the corresponding insets. (B) Scattered plot
lation coefﬁcient (r) between themeanH-score of CK2α and pStat3S727 (bottompanel). (C) Tabl
(D) Representative images taken froma section of rat C6 cell line derived intracranial tumor - H&
normal and tumor regions are delineated with a solid line. Images were captured at magniﬁcat
Graph represents percentage of positive nuclei in the normal and tumor regions (***p= 0.0001
(rat glioma), U87MGandDBT-RG 05MG (human glioma)were immunoblotted to check the lev
is plotted in the graph.quantitative scoring method was used and H-score was generated as de-
scribed previously [20] which were used for further statistical analysis.
The human samples contained a collection of grade II, III and IV glioma
tumor sections (n = 23) with adjacent normal portions wherever
possible.2.7. Immunoﬂuorescence microscopy
C6 cells were subjected to immunoﬂuorescence studies after the
indicated treatment according to previously described protocol [23].
Images were captured using DP71 camera in BX-61 microscope and
analyzed using Image Pro Plus imaging software.lue
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(A) Representative images of tumor regions taken from 23 human glioma patient samples
against pStat3S727, pStat3Y705 and CK2α. Imageswere captured atmagniﬁcations of 200×.
representing the mean H-score of the tissue samples (top panel). Graph represents corre-
e depicts the score fromKruskal–Wallis andWilcoxon–Mann–Whitney statistical analyses.
E stained sections and sections immunostainedwith CK2α, pStat3S727 and pStat3Y705. The
ions of 400× (A section from each image has beenmagniﬁed in the corresponding insets.)
). (E)Whole cell lysates (WCLs) from normal rat astrocytes (NRA) and glioma cell lines C6
els of pStat3S727 and CK2α. Pearson's correlation coefﬁcient (r) between these two proteins
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Cell viability was measured by usingMTT [3-(4, 5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide] which is reduced to purple
formazan in themitochondria of living cells. 10,000 cells/well were seed-
ed in a 96-well plate and allowed to grow for 48 h. Following the removal
of culture medium, cells in 96-well plates were incubated with 1 mg/ml
MTT for 4 h. The medium was aspirated and the formazan solubilised in
100 μl DMSO. The optical density of each sample at 570 nm was mea-
sured in VICTOR X Multilabel Plate Reader (PerkinElmer, Waltham, MA,
USA). Quantiﬁcation was based on three independent experiments.2.9. Soft-agar colony formation
For soft-agar assays, 2000 cellswere suspended in DMEMcontaining
0.35% agar and layered on top of 1 ml of DMEM solidiﬁed with
1.0% agar in each 35 mm dish. After growing at 37 °C for 14 days,
colonies were visualized in different microscopic ﬁelds and images
captured in Olympus IX81 microscope using Image Pro Plus imaging
software.0
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Fig. 2. CK2 negatively regulates phosphorylation of Stat3 at Ser-727 but affects its transcri
DMAT for 6 h, followedby immunoblotting ofWCLs for pStat3S727 and Stat3 (left panel). CK2 ac
for pStat3S727 and Stat3 (right panel). Comparison of densitometric scan values iswith respect t
were immunostained with pStat3S727 or pStat3Y705 (primary) and AlexaFluor594 or AlexaFluo
along with DAPI stained nuclei at 600×magniﬁcation (A section from eachmerged image has b
intensity or pStat3Y705 nuclear staining intensity in the control and treated cells (**p= 0.002, *
and CK2α-CK2β (right panel). Lysateswere prepared from36h post-transfected cells andprobe
CK2β (right panel). (D) C6 cells were treated with inhibitors of CK2, PI3K-Akt and MAPK — TB
pStat3S727, pStat3Y705 and Stat3 (Comparison of densitometric scan values is with respect to St
After 42 h of transfection, including the last 6 h with TBCA, WCLs were prepared and luciferase
values represent the mean (±) S.D. from three independent transfections (***p= 0.001). (F) C
performed using total RNAs extracted from the treated cells.2.10. FACS analysis
Cells were trypsinized and washed in PBS, pelleted, resuspended
in ice-cold 70% ethanol for ﬁxation and kept overnight at −20 °C.
After washing two times in PBS, cells were resuspended in PI/
RNase staining buffer (BD Pharmingen, Franklin Lakes, NJ, USA)
and incubated in dark for 15 min at ambient temperature. Cell
cycle distribution was examined by ﬂow cytometry using a LSR
Fortessa ﬂow cytometer (BD Biosciences, Franklin Lakes, NJ, USA)
and analyzed using WinMDI 2.9 software (http://facs.scripps.edu/).
2.11. Matrigel invasion assay
Cell invasion was assayed by using BD Biocoat™matrigel invasion
chambers with 8 μm PET membrane. 50,000 cells were suspended in
0.5 ml of 0.4% serum containing medium and were added to the upper
chamber. DMEM containing 10% fetal bovine serum was used as
chemoattractant in the lower chamber. The cells were incubated for
16 h in a humidiﬁed CO2 incubator at 37 °C. Cells that traversed the
8 μmmembrane pores and spread to the lower surface of themembrane
were stained with 5% Giemsa solution and were counted in ﬁvepStat3S727
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1729T. Mandal et al. / Cellular Signalling 26 (2014) 1725–1734different ﬁelds. Each experiment was carried out in triplicate and error
bars represent the mean S.E.2.12. Orthotopic tumor model
All animal care and experimentation conformed to the CPCSEA
guidelines. To generate the tumor model, Sprague–Dawley rats
weighing approx. 200 g were intracranially injected with early passage
C6 cells (normal and stable cell lines) (1 × 106) once. After 21 days, tis-
sue samples of both tumor and adjacent normal regions of brain were
collected and ﬁxed in 10% buffered formalin and embedded in parafﬁn
for further histological and histochemical analysis.2.13. Syngenic tumor model in ﬂanks
To generate this tumormodel, Sprague–Dawley ratswere injectedwith
EV, Stat3 WT and Stat3 mutant cells (1 × 106) in the ﬂank region once.
Growth of the tumors was observed for a period of 14 days after which
the rats were sacriﬁced and tumors were excised for further analysis.2.14. Statistical analysis and densitometry
All statistical calculations were done using GraphPad (QuickCalcs,
http://www.graphpad.com/quickcalcs/index.cfm) calculator. Scores for
U-test and H-test were calculated manually. For the analysis of statisti-
cal signiﬁcance, Student's t-test (unpaired)was used. In all experiments
a value of p b 0.05was taken as statistically signiﬁcant. Quantiﬁcation ofSo
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Fig. 3.Dephosphorylation at Stat3 Ser-727 by PP2A causes its negative regulation by CK2. (A) & (
in addition to 0.5 M sorbitol for the indicated time periods. WCLs were prepared and immunob
Stat3 intensity. (C) C6 cells were treated with 0.5 M sorbitol for 1 h and calyculin A for 0.5 h. W
actin. (D) HEK293 cells were transfected with PP2A-Cα. WCLs were prepared 36 h post transf
extractswere prepared fromC6cells treatedwith okadaic acid for 4 h followedby immunoblotti
with pGL3–c-jun luciferase reporter plasmid. After 36 h of transfection, cells were treated wit
activity was measured in triplicates. Results are presented in terms of fold change and the va
and 0.0011 respectively).nuclear localized protein and densitometric scanning of immunoblots
were done using Image J software (Bethesda, MD, USA).3. Results
3.1. pStat3S727 is less frequent when compared to CK2 expression in glioma
As both CK2 and pStat3S727 are oncogenic proteins and has been
implicated in GBM, a correlation study between these two proteins
was done. Immunohistochemical analysis of tissue samples from 23
human glioma patients (grades II, III and IV) for these two proteins
showed perceptible nuclear presence. CK2 is highly overexpressed
in glioma whereas the presence of pStat3S727 is visibly less when com-
pared to normal sections of the brain tissue (Fig. 1A). In accordance
to earlier reports [24], pStat3Y705 was found to be overexpressed in
the glioma patient samples compared to normal brain samples. The
staining intensities of pStat3S727 and CK2α proteins were quantiﬁed,
where a very weak degree of negative correlation was obtained
(Pearson's correlation coefﬁcient, r = −0.0231) (Fig. 1B). Statistical
analysis of the H-scores by Kruskal–Wallis and Wilcoxon–Mann–
Whitney tests conﬁrmed that the differences in staining intensities of
the two proteins were indeed statistically signiﬁcant (Fig. 1C).
Next, we tested the existence of correlation between CK2 and
pStat3S727 in rat glioma, which was proved earlier in human glioma tis-
sues. To examine this, a C6 glioma cell line derived orthotopic tumor
model in Sprague–Dawley ratswas used. Thismodel has beendescribed
extensively in a previous report [22]. Sections from the orthotopic tu-
mors were prepared such that they contained adjacent normal andrb
B
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by hematoxylin and eosin (H& E) staining. Upon examination of the ex-
pression of CK2α and pStat3S727 in these tissue sections and quantiﬁca-
tion of number of positive staining nuclei, it was found that CK2α levels
were upregulated in tumors when compared to normal tissue but the
change in pStat3S727 levels was not quite signiﬁcant (p = 0.054)
(Fig. 1D). It was interesting to note that overall cellular CK2α staining
intensity remained similar in both normal and tumor regions but its
presence was prominent in the nucleus of the tumor cells reﬂecting its
nuclear role in glioma. pStat3Y705 levels were found to be increased in
tumor regions of ratmodel as well. When the status of CK2α expression
and pStat3S727 was checked in normal rat astrocytes and glioma
cell lines (C6 rat glioma; U87MG and DBT-RG05MG human glioma), a
high degree of negative correlation (r =−0.94653) was established
(Fig. 1E). Thus, CK2 andpStat3S727 both play an important role in glioma
and theremay exist amechanism bywhich these two crucial factors act
for glioma progression.
3.2. Phosphorylation of Stat3 at Ser-727 is negatively regulated by CK2
As CK2 and pStat3S727 show a negative correlation, we tried to study
themolecularmechanism for this phenomenon. To examine this, C6 gli-
oma cells were treated with known inhibitors TBCA and DMAT for CK2.
Inhibition of CK2 activity resulted in increased pStat3S727 level (Fig. 2A,
left panel). On the contrary, enhancing the activity of CK2 by treatment
with 0.5 M sorbitol decreased pStat3S727 level (Fig. 2A, right panel).
Again, immunocytochemical analysis of C6 cells upon CK2 inhibition
showed elevated levels of phosphorylated Stat3 at Ser-727 (Fig. 2B,
left panel). Conversely, pStat3S727 levels were reduced when CK2α,R
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analysis of Stat3 target genes was performed using total RNAs extracted from the treated cells.
prepared and immunoblotted for bcl-xl, Cyclin D1 and SOCS3. (C) HEK293 or U87MG cells we
target genes. (D) CK2α′/β was transiently transfected in HEK293 cells. 36 h post-transfec
(E) HEK293 cells were transfectedwith Stat3 S727A followed by RNA extraction and qRT-PCR a
the mean (±) SE.CK2α′ or CK2βwas exogenously overexpressed (Fig. 2C). Interestingly,
a decrease in pStat3S727 levels leads to elevated level of pStat3Y705 when
CK2 is exogenously overexpressed (Fig. 2C). This reverse effect on Stat3
Ser-727 phosphorylation and Stat3 Tyr-705 phosphorylation was also
observed when CK2 was inhibited by TBCA (Fig. 2B, right panel and
D). When an inhibitor for MEK pathway, U0126, was used, as expected,
pStat3S727 phosphorylation was reduced with concomitant increase in
pStat3Y705 levels (Fig. 2D).
Further, to evaluatewhether perturbation in pStat3S727 levels result-
ed in altered transcriptional activity of Stat3, C6 cells were transfected
with pGL3–c-jun promoter plasmid, containing Stat3 binding site
(GAS sequence — TTCCCGGAA), along with inhibition of CK2 activity.
In this context of increased pStat3S727 and reduced pStat3Y705 levels,
Stat3 transcriptional activity was found to reduce signiﬁcantly
(Fig. 2E). When C6 cells were treated with 0.5 M sorbitol, transcription
of Stat3 target genes was enhanced upon increased CK2 activity and
thereby reduced pStat3S727 level (Fig. 2F). CK2, therefore, seems to neg-
atively regulate Stat3 Ser-727 phosphorylation but positively affects its
transcriptional activity. Alternatively, it appears that pStat3S727 impedes
the transcriptional potential of Stat3.
3.3. Negative regulation of Stat3 Ser-727 phosphorylation by CK2 is
mediated via PP2A
CK2, being a kinase, has no phosphatase activity. Therefore,
its negative regulation of Stat3 Ser-727 phosphorylation warrants
the mediation of a third party phosphatase. Overview of literature
proposes a serine/threonine protein phosphatase, PP2A, which is
regulated by direct interaction with CK2α [25]. PP2A is also known0
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nalysis of Stat3 target genes. Experiments were repeated three times and values represent
1731T. Mandal et al. / Cellular Signalling 26 (2014) 1725–1734to dephosphorylate Stat3 and inﬂuence its activity [26,27]. Consequent-
ly, C6 cells were treated with PP2A inhibitors okadaic acid and calyculin
A, for the time periods indicated in the ﬁgure legend, along with 0.5 M
sorbitol which induces CK2 activation. It was noted that sorbitol
induced decrease in pStat3S727 level was restored signiﬁcantly when ei-
ther okadaic acid (Fig. 3A) or calyculin A (Fig. 3B) was used. Although
extremely transient, to analyze the possible physical interaction of
PP2A and pStat3S727, PP2A was immunoprecipitated and was found
to interact with pStat3S727 when activated by CK2 in the presence of
sorbitol. This interactionwas diminishedwhen calyculin Awas used be-
cause of the reduced activity of PP2A (Fig. 3C). We further found that
when PP2A is overexpressed, a decrease in pStat3S727 level resulted
in increased Stat3 phosphorylation at its Tyr-705 residue (Fig. 3D,
left panel). Alternatively, when PP2A activity was inhibited in C6
cells by okadaic acid treatment and nuclear localization of pStat3Y705
and pStat3S727 was observed, it was found that level of pStat3Y705 de-
creased in the nucleus when compared to the control, whereas there
was an increase in pStat3S727 level in this condition (Fig. 3D, right
panel). Thus, reduced pStat3S727 level results in its increased func-
tional activity.
Effect of PP2A inhibition was also noticed upon pGL3–c-jun
promoter analysis, where sorbitol induced decrease in pStat3S727
levels ensued heightened activity of this promoter which was per-
ceptibly reducedon calyculin A treatment. Further, combined treatmentCyclin D1
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empty vector (EV) control. Phosphorylation status of Stat3 at Ser-727 and Tyr-705 was checked
were analyzed by immunoblotting ofWCLs from EV, Stat3WT andmutant cells. (C) C6 cell lines
cells per 35mm dish. After incubation for 14 days, colonies were visualized under microscope
were immunoblotted for Cyclin D1, Cyclin A and Cyclin B1 (cell cycle proteins) or MMP9, MMwith sorbitol and calyculin A was able to restore the promoter activity
partially (Fig. 3E). Accordingly, it may be suggested that activation of
CK2 increases the phosphatase activity of PP2A which in turn results
in dephosphorylation of Stat3 at Ser-727 thereby augmenting its tran-
scriptional activity.3.4. Effect of CK2 on the expression of Stat3 target genes
Stat3 is an established oncogenic transcription factor with several
targets that include anti-apoptotic proteins like BCL2 family proteins in-
cluding bcl-xl, MCL-1 and BCL-2, the proliferation-associated proteins
Cyclin D1 and c-Myc, pro-angiogenic factor VEGF, its feedback regulator
SOCS [28] and several others [12,29,30]. To analyze the effect of CK2
mediated downregulation of pStat3S727 on its downstream effectors,
qRT-PCR was done in various cell lines including DBT-RG05MG,
U87MG and HEK293. It was found that concomitant with our results
obtained from luciferase reporter assays, decreased pStat3S727 levels
upon sorbitol treatment or CK2α, CK2α′ and CK2β overexpression
favored its transcriptional activity which was translated into increased
expression of SOCS3, bcl-xl and Cyclin D1 genes in the human cell lines
(Fig. 4A, C and D). Increased levels of Stat3 target proteins SOCS3, bcl-xl
and Cyclin D1 were also observed upon overexpression or activation of
CK2 (Fig. 4B).T
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1732 T. Mandal et al. / Cellular Signalling 26 (2014) 1725–1734To mimic the decreased phosphorylated state of pStat3S727 due to
overexpression or activation of CK2, HEK293 cells were transiently
transfected with the plasmid containing Stat3 serine mutant, Stat3
S727A. The effect was similar and the mutant plasmid was also able to
increase the expression of bcl-xl, SOCS3 and MCL1 genes (Fig. 4E).
Thus, it is inferred that Stat3 Ser-727 phosphorylation acts antagonisti-
cally to its Tyr-705 phosphorylation in this context thereby affecting its
transcriptional activity negatively. Collectively, removal of the Ser-727
phosphorylation mediated by CK2–PP2A augments the expression of
several pro-survival and proliferative proteins which may ultimately
lead to cancer progression.
3.5. Reduced phosphorylation at Ser-727 residue enhances oncogenic
potential of Stat3
As evident from our ﬁndings, decreased Stat3 Ser-727 phosphoryla-
tion resulted in increased transcription of its downstream targets. This
effect was observed either by CK2 overexpression or ectopic expression
of Stat3 S727Amutant; whichmay be ultimately imperative in promot-
ing tumor progression. To conﬁrm this possibility, constitutively ex-
pressing stable C6 cell lines harboring either the Stat3 WT or Stat3
S727A mutation was established. Expectedly, pStat3Y705 levels wereEV Stat3 mut
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and mutant stable cells. (B) Representative image of the H & E stained sections of the orthotopi
either pStat3S727 or pStat3Y705 antibodies. Images were captured at magniﬁcations of 100×. Gra
mutant stable cell derived tumors. (D) Representative images of the tumor sections immunostai
comparative analysis ofH-score of the aboveproteins in EV, Stat3WT andmutant stable cell der
volume (top panel) and tumor size (bottom panel).high in both cell lines when compared to the EV control (Fig. 5A). Phos-
phorylation at Stat3 Ser-727 residue was also high in the Stat3 WT cells
when compared to the EV or mutant cells. When the effect of these
phosphorylation changes was analyzed in downstream proteins, it
was observed that though the expression of SOCS3 increased in both
cell types when compared to EV control, level of bcl-xl, a well known
survival protein, was highly increased in the Stat3 mutant cells which
may be due to the negative regulation of Stat3 DNA binding activity
by its Ser-727 phosphorylation (Fig. 5B). The rate of cell proliferation
was also found to be more in the mutant cells compared to the WT
and EV control cells as assessed by MTT proliferation assay (Fig. S1).
To determine the anchorage independent growth potential of the
Stat3 mutant cell line, soft-agar colony formation assay was performed.
Again, themutant cells produced relatively larger colonies than both the
WT and EV control cells (Fig. 5C). Increased proliferative capacity of the
Stat3 S727A mutant cells was further conﬁrmed by analysis of the cell
cycle proteins, Cyclin D1, Cyclin A and Cyclin B1 (Fig. 5D). Cell cycle
analysis by FACS also corroborated this conclusion as more number of
cells was in the S and G2/M phases in the mutant cells compared to
either the WT or EV control cells (Fig. S2).
To be metastatic and tumorigenic, cancer cells need to invade
through basement matrix of tissues and inﬁltrate surrounding regions.0
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and VEGF, which increases vascular permeability and angiogenesis
showed increased expression in the mutant cells compared to both
theWT and EV (Fig. 5E). Interestingly, these proteins are also Stat3 tran-
scriptional targets [31–34]. Matrigel invasion assay conducted to assess
the invasive potential of these cells showed more number of cells
migrating to the lower compartment of the Boyden chamber in case of
the mutant cells compared to the EV control (Fig. S3). Hence, increased
transcriptional activity of the Stat3 S727A mutant cells resulted in
increased proliferative, metastatic and angiogenic potentials of these
cells, which are hallmarks of cancer [35], marking them for cancer
progression.3.6. Reduced pStat3S727 levels lead to the development of more aggressive
tumors in vivo
To conﬁrm that the Stat3 S727Amutant cells indeed have enhanced
tumorigenic potential, the EV, Stat3 WT and Stat3 mutant cells were
injected into respective rat brains to create an orthotopic tumor
model. Tumors were obtained after approx. 3 weeks (Fig. 6A) and
their morphological features were ascertained by H & E staining
(Figs. 6B and S4). Immunohistochemical analysis of the tumor sections
conﬁrmed that pStat3S727 levels were less and pStat3Y705 levels were
more in Stat3 mutant cells generated tumors when compared to the
WT or EV generated ones (Fig. 6C). Increased expression of PCNA and
VEGF, markers for cell proliferation and angiogenesis, was also found
in the Stat3 mutant generated tumor when compared to WT or EV
generated one (Fig. 6D). To determine if the Stat3 mutant cells could
form more aggressive tumors, the WT, mutant and EV cells were
injected into ﬂanks of SD rats and tumor development was monitored
progressively up to 14 days (Fig. S5). Comparison of size and volume
of tumors (Fig. 6E) from the three sets of rats conﬁrmed our hypothesis
that the Stat3 S727A mutant cells had increased tumorigenic potential
and could form more aggressive tumors when compared to either the
WT or EV cells.JAK1/2
CK2
P
pStat3Y705
PP2A
pStat3S727
Oncogenic signalLigand
bcl-xl, MCL1, cyclin D1, 
MMP9, VEGF
Survival
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Fig. 7. This model depicts the regulation of Stat3 Ser-727 phosphorylation by CK2 and
the ensuing effect on cell survival, proliferation and angiogenesis. Upon stimulation by
an oncogenic signal, CK2 gets activated which in turn can phosphorylate Jak2 and induce
Stat3 Tyr-705 phosphorylation. Alternatively, CK2 can also induce the activity of a protein
phosphatase, PP2A, which then dephosphorylates Stat3 at Ser-727 residue. Reduction of
Stat3 Ser-727 phosphorylation by CK2 leads to enhanced Stat3 activity and heightened
expression of its target genes. Increased cell survival, proliferation and angiogenesis follow
leading to more aggressive tumor progression.4. Discussion
Oncogenic role of Stat3 is a much established fact and warrants no
further discussion [12,29,36]. Activation of this protein is mainly by
phosphorylation at its Tyr-705 residue whereby it dimerizes, enters
the nucleus and mediates its role as a transcription factor [29]. Apart
from this, several reports have entailed phosphorylation of Stat3 at
Ser-727 residue to be another important event for the regulation of
its transcriptional activity. Stat3 Ser-727 phosphorylation has been
reported to be effected by various kinases like Erk, H7 sensitive kinase,
protein kinase Cδ, nemo-like kinase, cyclin-dependent kinase 5,
mammalian target of rapamycin kinase, death-associated protein kinase
3 andmitogen- and stress activated kinase 1 depending on the cytokine
stimulation and the type of cell used for the experiment [37–41].
On evaluating the role of pStat3S727, it was found that it could either
positively affect the Stat3-mediated gene activation [42,43] or repress
the activity of Stat3 [19,37,41]. Another report also suggests that there
may be no effect on Stat3 DNA binding activity as a result of Stat3 Ser-
727 phosphorylation [44]. This contradictory role of Stat3 Ser-727 phos-
phorylation may be due to the different stimulus used or the difference
in cellular environment which leads to altered post-translational modi-
ﬁcations of proteins thus affecting their function. In certain tumors,
where Stat3 was implicated for oncogenesis, activation of Stat3 was
found to be the result of phosphorylation at both Tyr-705 and Ser-727
residues [36,45–47]. Although no report till date details the role of
pStat3S727 in glioma progression, elevated levels of this phoshoprotein
have been reported in GBM patient samples but not in GBM cell lines
[18]. Contrary to this ﬁnding of Brantley et al., we found that pStat3S727
was negligibly elevated in glioma when compared to normal tissue
and was either cytoplasmic or poorly localized in the nucleus of tumor
samples. The level of pStat3S727 was also reduced in glioma cell lines
when compared to normal rat astrocytes suggesting a deleterious
effect of this form of Stat3 on glioma progression. The regulation of
this post-translational modiﬁcation of Stat3, therefore, is vital in glioma
pathogenesis.
Novel regulatorymechanisms of Stat3 Ser-727 phosphorylationmay
lead to better understanding of the nature of tumor progression. In
our study, we checked the effect of a serine/threonine kinase CK2 in
pStat3S727 regulation; CK2 is known to activate the Jak–Stat signaling
pathway via interactionwith Jak2 [11]whichmediates phosphorylation
of Stat3 at Tyr-705 residue. Supporting the report by Dixit et al. [7], we
found heightened CK2α expression in glioma, which was prominently
nuclear in tumor cells, substantiating its pro-oncogenic role and also
exhibiting a converse relation to pStat3S727 levels. As expected, upon
overexpression, CK2α could induce Stat3 transcriptional activity as a re-
sult of reduced pStat3S727 level with concomitant increase in pStat3Y705
level. The negative relationship between pStat3S727 and pStat3Y705 has
been discussed in previous reports where enhancement in pStat3S727
levels was associated with decreased pStat3705 levels and reduced tran-
scriptional activity [48,49].Wakahara et al. have proposed amechanism
for this negative regulationwhichworks largely through a protein tyro-
sine phosphatase, TC45 [41]. That the reduced Ser-727 phosphorylation
level of Stat3 was responsible for its enhanced transcriptional activity
in our ﬁndings provide an insight as to why the pStat3S727 level is not
enhanced in glioma when compared to normal tissues.
PP2A forms stable complexeswith various proteinmolecules, there-
by establishing itself to be a major regulator in cellular signaling by re-
versible protein phosphorylation. Though PP2A has been suggested to
be a tumor suppressor [50], caution must be exercised before referring
to the different PP2A complexes in generic terms. Reports exist where
PP2A tumor suppressive activity has been inhibited for the promotion
of cellular transformation [51–53]. Indeed, in our study, we suggest
PP2A to have an indirect tumor promoting function by dephosphorylat-
ing Stat3 Ser-727 which in turn increases the transcriptional activity of
Stat3. Thus, in glioma, CK2 may play its pro-oncogenic role by associat-
ing with PP2A, activating it and resulting in altered activity of Stat3.
1734 T. Mandal et al. / Cellular Signalling 26 (2014) 1725–1734Corollary to our c-jun promoter analysis studies, increased tran-
scriptional activity of Stat3 upon reduced phosphorylation at its
Ser-727 residue was reﬂected in the increased expression of its target
genes like bcl-xl, SOCS3, MCL1 and Cyclin D1. As these genes are in-
volved in cell survival (BCL-2 family genes) and cell cycle (Cyclin D1),
a stable cell line overexpressing the Stat3 S727A mutant had a greater
survival and proliferative capacity. These cells were also more invasive
and expressed increased amount of the angiogenic protein VEGF,
distinguishing them as precursors to cancer progression. Indeed, these
cells could also form larger tumors in vivo. Thus, Stat3 activation by
reduced Ser-727 phosphorylation confers multiple advantages on the
glioma cells that are essential for successful malignancy (See Fig. 7).
Targeting Stat3 activity has been the method of choice for therapies
against cancer [54–56] and our study provides a novel axis for explora-
tion in this direction.
5. Conclusions
In our study we establish that i) Stat3 activity is regulated by CK2 at
its Ser-727 residue, ii) PP2A is activated upon CK2 activation and acts as
the dephosphorylating agent for pStat3S727, iii) Stat3 Ser-727 mutant
cell line could enhance glioma cell survival, proliferation and invasion,
and iv) In vivo rat model grew more aggressive tumors due to reduced
level of pStat3S727 with enhanced pStat3Y705 level. Thus our study eluci-
dates a novel axis for Stat3 activation which may be targeted for effec-
tive glioma therapy.
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